Multiple Myeloma Flashcards
What is Multiple Myeloma (MM)
plasma cell neoplasm characterized by clonal proliferation of malignant cells in the bone marrow, monoclonal protein in the blood and urine, and associated end organ dysfunction
Diagnosis criteria for MM
Presence of > 20% plasma cells in bone marrow (or biopsy of a tissue with monoclonal plasma cells)
Monoclonal protein in the serum or urine
and
Evidence of end organ damage (CRAB criteria: calcium elevation, renal insufficiency, anemia, or bone marrow lesions)
MM incidence
Peak incidence in the 70s, medican age 70 years old
Blacks most affected, men more affected
Most common primary bone malignancy
S and S of MM
- Bone pain: mostly in back and thoracic and pathologic fxs from osteolytic lesions
- anemia
- recurrent infections
- nausea and vomiting
- delirium from hypercalcemia
- neuro complications: blurred vision, spinal cord compression
- purpura and epistaxis from thrombocytopenia
- paresthesia
- weight loss
- generalized weakness
peripheral smear for MM
Normochromic, normocytic anemia
rouleaux formation
labs for MM
- hypercalcemia
- elevated BUN, creat, uric acid, total protein
- Proteinuria from overproduction and secretion of free monoclonal kappa or lambda chains (bence jones protein)
- Increased IgG and IgA
- hyponatremia
- nests and sheets of plasma cells in bone marrow
- Serum beta 2 microglobulin >8
- elevated serum lactate (poor prognosis)
- abnormal chromosomes
Durie-Salmon MM Staging: stage 1
Hemoglobin >10 Calcium <12 normal bone xray or 1 lesion Low M component production IgG <5 IgA<3 Urine light chain < 4 g/24h
Durie-Salmon MM Staging: stage 2
doesn’t fit stage 1 or 3
Durie-Salmon MM Staging: stage 3
One or more of the following: Hemoglobin< 8.5 Calcium >12 Advanced lytic bone lesions High M component production IgG >7 IgA> 5 Urine light chains >12/24h
xrays for MM
areas of pain usually have punched out lesions on xray or osteoporosis, use CT if unclear
MRI fo MM
preferred method of imaging for spinal compression or soft tissue plasmacytomas.
MM tx
All transplant eligible pts should be considered for 12 week induction chemo with triplet regimens.
If response good then move on to stem cell mobilization and collection
PAtients with high risk characteristics should be offered autologous stem cell transplant (ASCT) up to age 75
Single ASCT improves survival by 12 months
Induction therapy for transplant eligible pts
VRD regimen: dexamethasone, lenalidomide, and bortezomib)
OR
CyBorD: cyclophosphamide, lenalidomide, dexamethasone
MM survival
median survival, 10 years in patients with no lytic bone lesions and serum myeloma protein concentration <3